Welcome to the real world Matthew Gordon examines the differences between observational studies and phase III clinical trials(more)
Drug regulation: still room for improvement The Medicines Act is 40 years old this year, but regulations and regulators have to change to keep up with rapid changes in medicines and society, says Les Rose.(more)
The downside to downsizing Monday , May 24, 2004
The downside of downsizing will be obvious to employees who are 'let go' - but what about the impact on the company? Will it necessarily be leaner and fitter?...(more)
Addressing the gender divide Thursday , May 20, 2004
Addressing gender inequalities in healthcare provision could improve male health, if the NHS can be persuaded to change its thinking, and pharma could benefit too....(more)
Giving patients more choice Saturday , May 01, 2004
The government's efforts to provide more patient choice in the NHS will open up opportunities and threats for the pharma industry. But is it reality or just rhetoric?...(more)
Targeting the new prescribers Saturday , May 01, 2004
As the first wave of supplementary prescribers start work, understanding where they fit into local health economies will help pharma forge stronger relationships....(more)
Supporting the everyday experts Saturday , May 01, 2004
People living with chronic diseases can be experts on their condition and, if properly supported, can make a positive impact on their own disease and quality of life....(more)
The brave new GMS world Saturday , May 01, 2004
Dr Stephen Head says parts of the new GMS contract represent a 'dumbing down' for doctors, but open up a number of new opportunities for enterprising pharma....(more)
